Here’s the RCT paper: “Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation” by Stephen J. Nicholls, MBBS, PhD; Steven E. Nissen, MD; Cynthia Fleming, RN, MSN; et al.
https://jamanetwork.com/journals/jama/fullarticle/2808864?gu...
“Oral doses of 30 mg to 800 mg for 14 days resulted in increasing muvalaplin plasma concentrations and half-life ranging from 70 to 414 hours. Muvalaplin lowered Lp(a) plasma levels within 24 hours after the first dose, with further Lp(a) reduction on repeated dosing. Maximum placebo-adjusted Lp(a) reduction was 63% to 65%, resulting in Lp(a) plasma levels less than 50 mg/dL in 93% of participants, with similar effects at daily doses of 100 mg or more.”
